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Abstract: Tricuspid valve endocarditis (TVE) is a growing concern with increasing rates and mortality 
burden. The currently changing etiology, the antibiotic resistance and the raise in iatrogenic causes as with 
implantable cardiac devices [cardiac implantable electronic device (CIED)], represent a challenge for the 
management of these patients. The progressively widespread use of CIEDs is adding to the more commonly 
known intravenous (IV) drug abuse in the list of causes. Treatment strategies include medical therapy alone 
or surgery. From the surgical standpoint tricuspid valve repair, replacement or the staged procedure of 
valvectomy as bridge to replacement are available options. Treatment of endocarditis related to implantable 
device is another expanding field which requires a coordinated action with microbiologists in consideration 
of the microorganism antibiotic resistance. This review summarizes the currently available evidences on TVE 
including surgical indications, timing of interventions and technical considerations. The conflicting results of 
the available observational evidences and the non-unanimous consensus on many aspects of TVE impede to 
reach a definitive conclusion regarding the best management strategy and demands for randomized studies in 
this field.
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Introduction
Tricuspid valve endocarditis (TVE) is defined as an 
infectious process of some portion of one or more leaflets 
of the tricuspid valve (TV). In developed countries, it is the 
most common cause of acute tricuspid regurgitation (TR). 
In a study of the Oxford University (1,2), the prevalence 
of TVE ranged among 5–10% of cases of heart valve 
endocarditis (HVE). Risk factors are intravenous drug use, 
cardiac device implant, central venous catheters, HIV, and 
congenital heart disease (CHD) (3,4). 
Despite being common among intravenous drug abusers 
(IVDUs), the increasing proportion of patients with cardiac 
implantable electronic devices (CIEDs) make this etiology 
a distinctive characteristic of TVE in the 21st century 
when compared to the 20th (5,6). The natural history of 
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TVE is heterogeneous and is largely determined by the 
severity of TR. Although a large proportion of patients 
have respiratory symptoms resulting from pulmonary 
emboli, pneumonia, and pulmonary abscess formation, 
the majority of them can be managed medically with good 
outcome (7). If left untreated, TVE with severe TR can lead 
to right ventricular dysfunction, heart failure, pulmonary 
hypertension, and atrial fibrillation. In the case of chordae 
rupture severe right heart haemodynamic dysfunction can 
rapidly occur. The mortality rate in TVE due to CIED 
is approximately 14.7% at 30 days to 23.2 % at 1 year (8) 
(Figure 1).
This review summarizes the currently available evidences 
on TVE including surgical indications, interventions and 
technical considerations.
We present the following article in accordance with the 
Narrative Review reporting checklist (available at http://
dx.doi.org/10.21037/atm-20-4685).
Figure 1 Summarizing clinical evaluation and diagnosis flowchart for TVE (see text for details and references). CIED, cardiac implantable 
electronic device; CoNS, coagulase-negative staphylococci; HIV, human immunodeficiency virus; IVDU, intravenous drug user; GP, general 
practitioner.
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Methods
A literature search of PubMed, EBSCO, Embase, Web 
of Science and Cochrane database of systematic reviews 
was performed, using the following keywords and MESH 
terms in various combinations: “endocarditis”, “infective”, 
“tricuspid valve”, “tricuspid valve repair”, “tricuspid valve 
replacement”, “tricuspid valvectomy”, “cardiac implantable 
device”, “pacemaker infection”.
The surgeon and the tricuspid anatomy
Accurate knowledge of the anatomy of the TV and the 
right ventricle (RV) is important for the surgeon during the 
repair or replacement procedure. The TV and subvalvular 
apparatus include valve leaflets, the annulus, papillary 
muscles and chordae tendinae.
TV leaflets
The valve has commonly 3 leaflets of unequal size but 
in some cases is possible to identify 2 (bicuspid) or more 
leaflets (9,10). The three leaflets are named according to 
their anatomic position as the septal, anterior-superior, and 
inferior leaflets (11). The anterior leaflet is generally more 
developed in length and width with radial direction, larger 
area and the greatest motion. Conversely, the posterior 
leaflet can sometimes be characterized by multiple scallops. 
The septal leaflet is the shortest with minimal mobility 
and inserts into the tricuspid annulus directly above the 
interventricular septum (12). The commissure between 
the septal and posterior leaflets is typically located near the 
ostium of the coronary sinus in the right atrium (RA). The 
anteroseptal commissure, which includes the septal and 
anterior leaflets, is the longest compared to the posterior 
one and located near the non-coronary sinus of Valsalva 
of the aortic root. The length of the commissure is due to 
the fact that the anterior and septal leaflets have the largest 
circumference. 
TV annulus
Despite valvular annulus is normally by a distinct fibrous 
structure, anatomical studies on healthy cadavers suggested 
that the term is improper for the TV annulus. In fact, 
the presence of fibrous tissue is very scarce and primarily 
localized in the septal segment of the annulus (13). The 
normal tricuspid annulus has a D-shaped with 2 distinct 
segments: a larger C-shaped segment which corresponds 
to the free wall of RA and the RV, and a shorter segment 
that appears straight and corresponds to the septal leaflet 
and the ventricular septum. The structure of the TV 
annulus makes it more fragile to traction during surgical 
manipulation. It is constituted by multiple muscular strands 
measuring approximately 2 to 4 mm in diameter, extending 
from the free wall of the RV and the septal wall. This 
peculiar morphostructure organized in muscle bands can 
offer support to the non-fibrous RA-RV junction which is 
therefore a weak part of the right heart. From histological 
point of view, it is constituted by very little fibrous tissue 
along with endocardium (13). 
Subvalvular apparatus
The anatomy of tensor apparatus of TV, which comprehends 
the papil lary muscles and chordae tendinae (14), 
play a pivotal role in TV repair even more when a 
cryopreserved homografts were used (15-18). The 
subvalvular apparatus of the TV is formed by the anterior 
and posterior papillary muscles and by a third papillary 
muscle whose existence is variable. Chordae tendinae of 
the TV consist of fibrous cords with different lengths that 
connect the papillary muscles to the TV leaflets.
The anterior papillary muscle is generally the most 
developed and gives rise the chordae tendinae which 
are destined to the anterior and posterior leaflet. The 
moderating band (trabecula septomarginalis) can be 
attached to this papillary muscle. The posterior papillary 
muscle often has two or three heads and the chordae 
tendinae intended for the posterior and septal leaflets 
derive from this papillary muscle. As for the septal 
papillary muscle, it is often variable, being small or 
multiple or even absent up to 20% of normal subjects. In 
the absence of the papillary muscle, the septal chordae 
tendinae can derive directly from the septum heading 
towards the anterior and septal leaflets. Therefore, the 
septal and anterior leaflets of the TV are connected to the 
interventricular septum and the anterior and posterior 
leaflets may depend on a large anterior papillary muscle 
located along the antero-lateral RV wall. 
Normally, the chordae vary in number from 17 to 36 
with an average of 25 and are differentiated in five types 
according to their morphology and site of attachment to 
the leaflet: fan-shaped, rough zone, basal, free edge, and 
deep chordae (18). The true chordae typically arise from 
the apical third of the papillary muscle but can also derive 
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from the ventricular walls, and in this case are attached to 
the septal leaflet (18,19). Chordae tendinae are constituted 
approximately by 80% collagen, whereas the remaining 
20% is made of elastin and endothelial cells. Accessory 
chordae tendinae can origin from the free wall of the 
RV and the trabecula septomarginalis. The subvalvular 
apparatus may be constituted by false chordae that are 
inserted in various parts and connect the two papillary 
muscles, a papillary muscle with the ventricular wall, or two 
points of the ventricular wall (18).
Biomechanics
From the biomechanical and ultrastructural points of 
view difference exists between the chordae tendinae of 
the tricuspid and the mitral valve. In the non-pathological 
human TV, the chordae tendinae consist of substantially 
straight bundles of collagen which are organized in a 
network of fibrils. This particular morphostructure 
provides less extensibility to the chordae when compared 
to the normal mitral valve’s ones of comparable size (20). 
The mechanical behavior of the chordae tendinae can 
explain the marked tethering occurring with the dilation 
of the RV or displacement of the papillary muscles. Mee 
et al. showed that excessive tethering in patients with 
Ebstein disease could be corrected with a papillary muscle 
reapproximation (21).
Surgical practical considerations 
A comprehensive anatomical knowledge of both the 
components of the TV and the adjacent structures is crucial 
in approaching TV surgery (Figure 2). When performing 
a TV repair operation, it should be considered that the 
coaptation of the TV is normally at or just below the 
annulus level, with a coaptation length of 5 to 10 mm (18). 
Conversely, an excess of coaptation length should be taken 
into account when using a homograft to replace or repair 
the TV (15-17). Importantly, due to the fact that the length 
of the chordae is fixed, the displacement of the RV septum 
or the side wall may affect the coaptation of the tricuspid 
leaflet. Therefore, wide coaptation length may function as a 
“reserve” when performing restrictive annuloplasty (15-17). 
Finally, the network of chordae can interfere with catheters 
and devices used during the interventional cardiological 
procedures, with additional challenge in transcatheter 
approaches. 
Etiology, pathophysiology and treatment
TVE is characterized predominantly by regurgitation. 
During the 20th century, the disease was common in 
younger and middle-aged adult patients with underlying 
rheumatic heart disease. The principal pathogen responsible 
for the infection was oral streptococci in high-income 
countries (22,23).
In the 21st century, with the growing development of 
antibiotic treatment, the risk profile of patients and the 
pathogen responsible for the infection changed. Patient 
demography includes IVDU, CHD and immunosuppression 
which became the main risk factors in the younger and 
middle-aged population (4,6,23-29). On the other hand, in 
older patients with increasing comorbidities, TVE is more 
associated to hemodialysis and permanent venous catheters. 
In fact, in the 21st century, with the expanding use of 
CIEDs a 25% increased incidence of iatrogenic infective 
endocarditis (IE) was registered in the cardiology practice 
(8,30,31). At the same time, staphylococci strains exceeded 
oral streptococci as the most frequent causative pathogen 
(32,33). Both pathogens can lead to leaflet damage and 
extensive infection. Colonisation of coagulase-negative 
staphylococci (CoNS) (e.g., Staphylococcus epidermidis, 
Staphylococcus lugdunensis, and Staphylococcus capitis) can lead 
to destruction of both valvular and subvalvular apparatus 
with nefarious evolution (34). Annular dilatation may also 
develop over time, leading to further progression of TR. 
Cardiac device infection is disproportionately growing 
in the United States compared to increasing implantation 
rates. CIEDs include permanent pacemakers, implantable 
cardioverter defibrillators, and cardiac resynchronization 
therapy devices (30), with an incidence of cardiac device 
infection after first implantation ranging from 1 to 10 
per 1,000 device/years. The rate of infection is variable 
considering the different types of device and it is 
approximately 1 per 1,000 device years for pacemakers and 
8 to 9 per 1,000 device-years for complex devices) (35-37). 
The concern associated with this complication is that 
patients with a CIEDs have an increase in short and long-
term morbidity and mortality as well as an increasing cost of 
management which is estimated at over $15,000 per patient 
(38,39). 
CIEDs infection may involve the generator pocket, 
device leads with an extension to endocardial tissue surfaces. 
The infection may be located on valvular and/or non-
valvular structures. Generally, in pocket infections cellulitis, 
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erythema, up to erosion of the device on the skin above 
the pocket can be seen. Patients who have an infection 
involving CIED leads or the endocardial surface (CIED-
IE) present systemic symptoms as fevers and rigors related 
to septicaemia. The pathogen implicated are Staphylococci 
strains (in particular CoNS) that represent 60–80% of 
cases (40). Surgical management of this infection is an 
expanding field. Risks associated to the procedure include 
the development of a postoperative hematoma [odds ratio 
(OR) 8.46; 95% confidence interval (CI), 4.01–17.86], 
Figure 2 Surgical anatomical consideration in TV surgery including TV components (top), and (bottom) anatomical structures located in 
proximity of the TV (left arrow) and subvalvular apparatus (right arrow). TV, tricuspid valve; SVC, superior vena cava; IVC, inferior vena 
cava; AV, atrioventricular; AVN, atrioventricular node.
Tricuspid Leaflets and Commissures
• Large valve orifice (9 cm2, with mean 
gradient <2 mmHg) 
• Usually 3 leaflets but variable (up to 6) 
or with deep clefts and folds
• Very thin, translucent leaflets
• The anterior leaflet is typically the 
largest, with the greatest motion
• Septal leaflet may be short radially, and 
is the least mobile
• D-shaped and flat along the septum 
Dynamic (larger in end-systole, early 
diastole, and atrial systole)
• Average perimeter =12 cm 
• Average area =11 cm2
• Heterogeneity in muscle and fatty 
tissues with discontinuous fibrous
Anatomic considerations of
structures adjacent to the TV
• Right atrium is thin-walled, markedly dilated in advanced disease
• SVC = mean length ~7 cm, maximum diameter ~2 cm, irregular in 
shape
• IVC = largest vein in the body (normally <21 mm)
• Coronary sinus enters right atrium at the commissure between the 
septal and posterior leaflet
• No continuity between inflow and outflow 
• Right coronary artery within the AV groove (variable transverse 
distance from annulus)
• AVN, bundle of His crosses the septal leaflet attachment 3 to  
5 mm posterior to the anteroseptal commissure
• Non-coronary sinus of Valsalva borders the anterior/superior annulus 
(commissure between the non-coronary/right coronary sinuses 
adjacent to the septal/anterior tricuspid leaflet commissure
• Large space to maneuver devices but more difficult for imaging
• Venous access considerations for new devices may be limited by 
SVC diameters and nonlinear shape. IVC annular angle may pose 
issues for device placement
• Inflow of the coronary sinus is a good anatomic marker of this 
commissure
• Little risk for outflow tract obstruction
• Short (~3–4 mm) transverse distance along the inferior annulus 
(adjacent to the posterior leaflet)
• Risk for heart block with devices in this region
• Risk for perforation with devices in this region
• Aortic sinuses of Valsalva may be used as an anatomic marker for 
the septal-anterior commissure
• The anterior papillary muscle is the 
largest, supplying chordal support to 
the anterior and posterior leaflets
• Septal leaflet chordae insert directly 
into the septum or with multiple, small 
papillary muscles
• An average of 25 chordae with various 
configurations composed of straight 
collagen bundles (thus less distensible 
than mitral chordae)
Tricuspid Annulus Chordae and Papillary Muscles
Nappi et al. Surgery of TVE
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Figure 3 Clinical algorithm for the management of TVE. IE, infective endocarditis; CT, computed tomography; PET, positron emission 
tomography; GMT, guide medical therapy; MRI, magnetic resonance imaging; SPECT, single-photon emission computed tomography.
reoperation for lead displacement with prolonged operation 
times. Surgical extraction and tricuspid reconstruction 
is sometimes necessary. Patients who require a revision 
procedure are exposed to a 2- to 5-fold higher risk of re-
infection. Use of antibiotic prophylaxis has been shown 
to protect against Clostridioides difficile infection (CDI) in 
both randomised controlled trials (RCTs) and observational 
studies (41). 
The approach to TVE requires consideration of 
several aspects including the causative pathogen, the 
premorbid conditions, the clinical conditions and potential 
deterioration and the extent of the infection and the 
decision-making in terms of treatment is guided by those 
parameters (Figure 3).
Patients with mild-to-moderate TR due to small 
vegetation may remain asymptomatic and without clinical 
deterioration or often have respiratory symptoms resulting 
from pulmonary emboli, pneumonia, and pulmonary 
abscess formation. However, TR imposes a volume load on 
the RV, which, if sustained over time, results in ventricular 
dilatation, neurohumoral activation and heart failure. In 
addition, elevation in the mean right atrial pressure leads to 
right atrial enlargement and atrial fibrillation (42-45).
The objective of surgery is to restore a valve competency. 
There are two main options for surgical correction of severe 
TR: TV replacement (TVR) or repair with annuloplasty 
(TVP) (46).
Tricuspid-valve replacement can be achieved with the 
use of either conventional mechanical or stented xenograft 
prosthesis. However, there are several disadvantages 
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associated to TVR. including the need for lifelong 
anticoagulation and the higher risk of thromboembolism 
with the use of mechanical valves. Conversely, the use 
of conventional xenograft valves has the drawbacks of 
structural valve degeneration with failure and the risk of 
prosthetic-valve endocarditis due to relapse of infection, 
especially in IVDUs. 
The goals of TVP are to obtain complete removal of 
infectious vegetation along with the valvular and subvalvular 
apparatus, to restore a proper line of coaptation on both 
leaflets, to reintegrate the continuity between leaflet and 
annulus of the TV, to correct annular dilatation, and to 
preserve (or repair, if necessary) the subvalvular apparatus 
(46-48). 
Clinical evidence
There is no randomized study investigating the ideal 
substitute in patients with severe TR due to TVE. However, 
evidence from observational series strongly suggests that 
surgical intervention is beneficial in IVDU and in infected 
CIEDs. A study from Cleveland Clinic (49) evaluated the 
impact of surgery on long-term outcomes of isolated right-
sided and left-sided IE with IVDU and CIEDs patients with 
chronic vascular access were the majority of the population. 
Patient were followed-up for a mean of 5.2 years. Surgery 
for TVE was used for 127 out of 134 patients of which 90 
patients had valve repair/reconstruction while 27 received 
a prosthetic valve replacement. Suture annuloplasty 
or combination of implant of artificial chords and an 
annuloplasty ring were used for repair/reconstructions the 
TV. The patients undergoing repair/reconstruction had a 
significantly better 5-year survival rate than those managed 
with a replacement (60% vs. 20%, P=0.03). Survival varied 
according to predisposing conditions. Five-year survival 
was 59% in patients with cardiac implantable devices and 
60% in IVDU. At 9-year follow-up mortality in CIEDs 
group was higher than IVDU (30% vs. 60% Plogrank=0.009). 
Survival was lower for patients with combined right- and 
left-sided IE than for those with isolated right-sided IE 
(P=0.03). The risk of infection relapse was higher in IVDU. 
Five-year freedom from reinfection was 87% with a rate 
of 76% in IVDU and 93% in the rest of the population. 
Incidence of reinfection did not differ significantly between 
those who had tricuspid repair/reconstruction compared to 
those were managed with replacement.
In another report from the Harvard group (25,50) 436 
patients with IE were studied, 78 of these were IVDUs. 
Right-side valve involvement was observed in 38 patients 
and 20 were IVDU. The largest number of patients (n=27) 
received a repair/reconstructions and a minimal percentage 
received replacement with a prosthesis or a cryopreserved 
homograft (25). Interestingly, after adjustments for 
baseline characteristics and propensity-score match, use 
of a homograft did not significantly affect early death (OR 
1.61; 95% CI, 0.73–3.40, P=0.23), overall death [hazard 
ratio (HR) 1.10; 95% CI, 0.62–1.94, P=0.75], or reinfection 
(HR 1.04; 95% CI, 0.49–2.18, P=0.93) (45). Overall, 10-
year survival rates were 69.5%±8.3% in IVDUs, and 
68.7%±3.9% in non-IVDUs, respectively (P=0.39). When 
adjusted by propensity score, IVDUs tended to have lower 
risk of early mortality (HR 0.32; 95% CI, 0.08–1.36; 
P=0.13) but with higher risk of late mortality (HR 2.07; 
95% CI, 0.78–5.48; P=0.14) compared with non-IVDUs; 
however, these trends were not statistically significant (25).
In a  recent  metanalys is  including 12 unmatched 
retrospective observational studies and 1,165 patients with 
a median follow-up of 3.8 years, TVP and TVR had similar 
short and long-term survival. TVP was associated with 
greater freedom from recurrent IE [relative risk (RR) 0.17, 
95% CI, 0.05–0.57, P=0.004] and reoperation (RR 0.26, 
95% CI, 0.07–0.92, P=0.04) but a trend toward greater risk 
of moderate to severe TR (RR 4.14, 95% CI, 0.80–21.34, 
P=0.09). Importantly, valve repair had lower risk for 
permanent pacemaker implantation (RR 0.20, 95% CI, 
0.11–0.35, P<0.001) (51).
There is no randomized evidence comparing surgery for 
TVE with medical treatment. Despite observational studies 
suggest a benefit of TV surgery (52), medical therapy 
alone can be effective for right-sided IE even when large 
vegetations were present (53). Aksoy et al. reported 426 
patients with a left-side endocarditis (LSE n=333) and a 
right-side endocarditis (RSE n=96) who received medical 
treatment or surgery (52). Using individual propensity 
scores, 51 patients who received medical and surgical 
treatment were matched with 51 patients who had medical 
treatment only. The analysis of patients characteristics and 
mortality were evaluated during a 5-year follow-up period. 
Regression analysis of the matched cohorts showed that 
surgery was associated with decreased mortality (HR 0.27; 
95% CI, 0.13–0.55). Presence of intravascular catheters 
at diagnosis was independently associated with increased 
mortality (HR 2.65; 95% CI, 1.31–5.33) (52). 
Otome et al. reported a retrospective analysis of 
consecutive 49 IVDUs with native TVE and compared 
tricuspid-valve surgery with medical treatment. No 
Nappi et al. Surgery of TVE
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difference in mortal i ty  was shown in relat ion to 
vegetation size in medically treated patients, however a 
bacteraemia score >4 was associated with a mortality of 
24% (P=0.026) (53).
A prospective cohort analysis from the International 
Collaboration on Endocarditis-Prospective Cohort Study 
(ICE-PCS) conducted in 61 centers in 28 countries 
reported 177 patients with CEIDs who developed IE (8). 
Vegetations of tricuspid-valve occurred in 24.3% of the 
patients. There was a significant survival benefit for patients 
undergoing surgery vs. medical therapy [1-year survival, 
19.9% vs. 38,2.5%; HR for death 0.42 (95% CI, 0.22–0.82)]. 
Staphylococcus and coagulase negative staphylococcal 
strains had significantly higher mortality rate (95% CI, 
28.0–42.5% and 24.9–39.0%, respectively). 
Mann et al. reported a significant involvement of the TV 
in 428 IE [native native valve endocarditis (NVE) n=283, 
prosthetic prosthetic valve endocarditis (PVE) n=199] 
retrospectively studied. A multivalvular involvement was 
shown in 19.1% of the patients, with 35.5% incidence of 
TVE (NVE =85, PVE =67). No significant difference in 
long-term survival was shown between NVE and PVE. 
Patients with IE caused by Staphylococcus aureus had 
higher 1-year mortality (28% vs. 18%; P=0.02) compared 
with non-S. aureus etiologies (54).
In a recent retrospective study from Australia, TVE 
had a lower incidence (38%) than left-sided IE (53%) in 
IVDUs. There was no significant survival benefit in patients 
with heart failure and large vegetation (>1 cm) undergone 
valve surgery (55). 
Surgery: indications and options
Patients with severe symptomatic TR or RV dysfunction 
should be offered surgery. Generally, these patients have 
vegetation size greater than 20 mm, worsening heart failure, 
and persistent infection. The increased pulmonary artery 
pressure (PAP) may determine morphologic changes with 
tricuspid annular and early right atrial and ventricular 
dilation. Patients with TVE with extension of the infection 
through the aortic non-coronary sinus or mitral valve 
(trigonal lesion), should be considered for surgery even 
without right ventricular dysfunction or dilatation, if 
pulmonary hypertension establishes (42,56).
Asymptomatic patients with mild to moderate TR, 
vegetations <1 cm, and no evidence of RV dysfunction or 
dilatation should receive antibiotic treatment and observed 
for clinical deterioration until symptoms or severe TR 
occurs (56).
Tricuspid-valve repair (TVP) is preferred to TVR 
procedure (48,49,54,56). Recently, surgeons from 
Kentucky (47) reported that TVR can be considered 
in young patients, bilateral emboli, and in infections 
sustained by methicillin-sensitive S. aureus (MSSA). 
For TVR, the use biological derivates over mechanical 
prosthesis is generally preferred for the lower risk of 
thromboembolic complication (16,25,26,49,54,56). 
Tricuspid-valve repair is recommended in older patients 
with clinically significant comorbidities, such as advanced 
respiratory, hepatic, or renal dysfunction, or those with 
recent pulmonary events or CIEDs (8). In first-time IE, 
TVP is preferred in IVDUs, while TVR is preferable in 
cases of reoperation of patients with high recurrence rate 
and in patients who require a reoperation for a PVE and 
extended infection. 
Another potential but controversial option regards 
surgical valvectomy as a temporary bridge therapy in 
attendance of staged TVR. The choice between valvectomy 
and valve replacement is also debated. In the presence of 
extensive lesions involving more than one scallop or more 
than one leaflet and in young patients, it is preferable to 
perform a TVR. In patients with persistent sepsis, abscess 
formation, ongoing drug use, and poor compliance to 
rehabilitation programs valvectomy is recommended (56). 
Despite pulmonary artery hypertension is a contraindication 
to valvectomy, patients with high pulmonary pressure can 
well tolerate valvectomy. This might be due to several 
factors: (I) large reserve of young patients, (II) a possible 
good physiological compensation secondary to long-
standing preoperative heart failure and (III) a perioperative 
improvement of PAPs secondary to the continued treatment 
of septic pulmonary emboli with effective targeted antibiotic 
therapy (57). 
The mortality rate after valvectomy varies across the 
literature compared with TVR. Several reports have shown 
a higher mortality in patients who received tricuspid 
valvectomy, but this discrepancy may be related to the type 
of pathogen involved, the advancements of perioperative and 
critical care, and more effective targeted antibiotic treatment 
over the course of the years (57-61). Protos et al. diverge 
from these conclusions reporting better survival (47). 
In IVDUs, the concern regarding the replacement of 
the TV is due to the fact that abuse relapse may result in 
infection of the prosthetic valve. Readmission rate at 1 year 
after discharge was less common in valvectomy. Factors as 
the pathogen sustaining prosthetic reinfection, antibiotic 
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resistance and emergency surgery are important in relapses 
after TVR. Conversely, in patients who received a tricuspid 
valvectomy as a bridge procedure hospital admission to 
perform valve replacement surgery is electively planned 
after 6 weeks of targeted antibiotic therapy, reducing the 
risk of the procedure. A recent meta-analysis has shown 
no differences in major cardiovascular events, infection 
recurrence and postoperative right heart failure when 
comparing valvectomy to TVR. Authors concluded that 
valvectomy could represent an acceptable initial bridging 
therapy for TVE giving time to identify candidates for 
staged valve replacement (48). This also has significant 
social and economic implications considering the costs for 
valve prosthesis clinical follow-up in non-compliant patients 
and the higher risk of emergent valve replacement in cases 
of reinfection vs. an elective valve implant in a staged 
procedure (62-64).
Surgery: technical considerations
In patients with isolated infection of the leaflet scallop 
of TV due to the IVDU, limited resection of infected 
leaflet is performed with the removal of the minimum 
number possible of adjacent chordae (15). The remaining 
segments of the TV leaflet are approximated. The annulus 
is reconstructed and supported with a prosthetic ring (17) 
although some surgeons prefer a DeVega annuloplasty 
(47,49,54), as avoids the use synthetic material. Limited 
resection and the use of artificial chordal replacement (with 
Gore-Tex expanded polytetrafluoroethylene sutures) and 
annuloplasty reinforcement may also be appropriate in cases 
of TVE with extended infection to subvalvular apparatus 
tissue. In patients with complex TVR a cryopreserved 
homograft valve replacement may be a suitable alternative 
to the use of conventional mechanical or stented xenograft 
prosthesis, especially when valve repair involves more 
leaflets or scallops. 
Extensive PVE or progression of primary infectious from 
aortic non coronary sinus or/and mitral valve through the 
trigone (trigonal abscess) can require demolitive surgery 
and in these cases the use of cryopreserved homograft 
is recommended (15-17). If the vegetation is located on 
antero-septal commissure or between anterior and posterior 
leaflet with no further involvement of leaflets scallops, 
reconstruction after excision of the infected segment can be 
performed using a partial homograft. Conversely, aortic-
tricuspid extension, circumferential aortic annular abscess or 
the development of intracardiac fistulas, requires complete 
debridement of the infected tissue and reconstruction with 
full homografts. In some instances, the use of cryopreserved 
mitral homograft in tricuspid position has been described 
(65,66). The use of homografts has also been found 
effective by the Harvard group (25,50). However, individual 
and institutional experience is crucial in determining the 
likelihood of success of a homograft procedure. High-
volume centers have the highest proportion of patients with 
complex IE and the lowest mortality rates.
From the technical standpoints, isolated tricuspid 
operations could be performed on beating heart venting 
and unloading the heart cavities. However, homografts 
procedures or more complex surgical interventions 
for extensive endocarditis might require to open the 
interventricular septum, RV or inter atrial septum and 
demands for full cardiopulmonary bypass.
The treatment of right sided endocarditis related to 
CIED is an emergent field (8,49,54) and recent reports 
are suggesting as delay in decision-making and lack of 
experience in this filed may result in intraprocedural and 
postoperative complications (67). The aim of surgery is to 
remove the infection, restore competence of the TV and 
reduce the risk of bacterial pulmonary embolism during 
removal of the infection. The extent of the infection 
guides treatment and if only the leads are involved, simple 
extraction of the infected material could be performed 
percutaneously (8,49). However, these procedures should 
be performed at the presence of a cardiac surgeon as the 
risk of RV rupture, especially when removing multiple 
catheters or long-term implants, is high and requires 
immediate sternotomy and surgical repair. Vegetations or 
damage of the TV demands for concomitant valve surgery 
including vegetectomy, leaflet repair with pericardial 
patch, TVP or TVR. From current reports analyzing 
the worrisome epidemiology of the problem and the 
causative etiology, it appears that the two tenets for an 
adequate management strategy of CIEDs-related TVE 
are the creation of dedicated endocarditis team composed 
by surgeons and cardiologist to avoid delay in diagnosis 
and treatment, and a stricter antibiotic prophylaxis policy 
directed to protect high-risk patients and to contain the 
increasing multidrug resistance (68). Another growingly 
important subset of patients at risk for TVE is represented 
by patients with end-stage kidney disease requiring 
vascular access and CIEDs. In these situations, risk-
reduction strategy foresees the creation of arteriovenous 
fistula on the contralateral upper limb for a CIED 
and avoidance of central vein catheter. The increasing 
Nappi et al. Surgery of TVE
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introduction of miniaturized CIEDs and even leadless 
pacemaker/implantable is an important perspective 




TVE is a surgical expanding concern with increasing 
rates and mortality burden. The progressively widespread 
use of CIEDs is adding to the more commonly known 
IV drug abuse in the list of causes. Surgical treatment 
includes valve repair, replacement or the staged procedure 
of valvectomy as bridge to replacement. However, the lack 
of specific randomized evidences and the non-unanimous 
results from the currently available observational evidences 
impede to reach a definitive conclusion regarding the best 
management strategy.
The recent advancement in antibiotic therapy and critical 
care add to the armamentarium of the surgeon in TVE, but 
the changing etiology, the antibiotic resistance and the raise 
of iatrogenic causes of IE demands further research efforts 
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